by Richard Cruse | Mar 31, 2021 | News
ProFactor Pharma Ltd (PFP) the developer of a unique, ultra high yielding cell line for the manufacture of recombinant human factor VIII (rhVIII), is pleased to announce the recent issuance of Indian Patent No. 361851 and Eurasian Patent No 529615EA. This patent...
by Richard Cruse | Jan 31, 2021 | News
Scottish biotech business ProFactor Pharma Ltd: (PFP) has completed the optimisation of its process for the manufacture of recombinant Factor VIII, for the treatment of Haemophilia A. In July 2020 we reported on the important development milestone that had been...
by Richard Cruse | Jan 19, 2021 | News
A year on from my last analysis of the World Federation for Hemophilia (WFH) Report on the Annual Survey we see in 2019 a further improvement in the number of people treated. However, we also see new data on the prevalence of the haemophilia A which suggests there are...
by Richard Cruse | Jul 15, 2020 | News
ProFactor Pharma Ltd (PFP), has completed an important development milestone in its programme to transform the treatment of ‘Haemophilia A’. The company has now received the second tranche of funding from its £2m funding round announced in September 2019 to advance...
by Richard Cruse | Jan 26, 2020 | News
We have been analysing the data provided by the World Federation for Hemophilia (WFH) for a number of years to develop our understanding of the market. Its Reports on the Annual Survey give details of the number of patients by country and the quantity of FVIII used....
by Richard Cruse | Nov 15, 2019 | News
Profactor Pharma Ltd is pleased to announce the appointment of Dr V Paul Gerskowitch to its board. Dr Gerskowitch joins the board of Profactor Pharma Ltd as an Investor Director with extensive, board level experience in the life sciences industries. He currently...
